Key Points
- Insider sale: Johanna Mercier sold 3,000 Gilead shares on Jan. 15 at an average of $124.31 for $372,930, leaving her with 103,221 shares (a 2.82% reduction in her holding).
- Pattern of recent selling: Mercier also sold 3,000 shares on Dec. 15 and 28,000 on Nov. 17, meaning insiders have disposed of over $4.26 million of GILD stock in recent months.
- Company backdrop: Gilead (market cap ≈ $155B) recently beat quarterly EPS estimates ($2.47 vs. $2.16), issued FY2025 guidance of $8.05–$8.25 EPS, and pays a $0.79 quarterly dividend (≈2.5% yield).
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the company's stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the transaction, the insider owned 103,221 shares in the company, valued at approximately $12,831,402.51. The trade was a 2.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Johanna Mercier also recently made the following trade(s):
- On Monday, December 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $122.00, for a total transaction of $366,000.00.
- On Monday, November 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00.
Gilead Sciences Stock Performance
Shares of NASDAQ:GILD opened at $124.91 on Friday. The firm has a market cap of $154.97 billion, a PE ratio of 19.37, a price-to-earnings-growth ratio of 0.64 and a beta of 0.33. The firm's 50 day simple moving average is $123.36 and its 200-day simple moving average is $118.02. Gilead Sciences, Inc. has a one year low of $91.68 and a one year high of $128.70. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the previous year, the business earned $2.02 earnings per share. Gilead Sciences's quarterly revenue was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. As a group, equities analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which was paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. The ex-dividend date was Monday, December 15th. Gilead Sciences's dividend payout ratio is currently 48.99%.
Wall Street Analysts Forecast Growth
GILD has been the topic of several research reports. TD Cowen raised their price target on Gilead Sciences from $115.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, October 23rd. The Goldman Sachs Group increased their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock a "neutral" rating in a report on Thursday, January 8th. Citigroup boosted their price target on shares of Gilead Sciences from $135.00 to $140.00 and gave the company a "buy" rating in a report on Wednesday, January 7th. Daiwa Capital Markets upped their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the stock an "outperform" rating in a research report on Thursday, November 13th. Finally, HSBC increased their target price on Gilead Sciences from $110.00 to $133.00 and gave the company a "hold" rating in a research report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $133.16.
View Our Latest Report on GILD
Hedge Funds Weigh In On Gilead Sciences
A number of institutional investors have recently bought and sold shares of GILD. Vanguard Group Inc. lifted its position in Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company's stock valued at $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 2.6% in the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company's stock valued at $3,231,548,000 after buying an additional 727,515 shares in the last quarter. Norges Bank purchased a new position in Gilead Sciences during the second quarter valued at $2,150,268,000. Invesco Ltd. increased its stake in Gilead Sciences by 12.0% during the 3rd quarter. Invesco Ltd. now owns 15,139,681 shares of the biopharmaceutical company's stock worth $1,680,505,000 after buying an additional 1,618,453 shares in the last quarter. Finally, Amundi lifted its holdings in Gilead Sciences by 18.2% in the 2nd quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company's stock valued at $1,167,221,000 after purchasing an additional 1,614,355 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.
Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
